On November 4, the website of the Shanghai Stock Exchange showed that the IPO application of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. (hereinafter referred to as "Shanwaishan") for the Science and Technology Innovation Board has been accepted.
It was learned from the official website of Shanwaishan that the company was established in 2001, is a national high-tech enterprise specializing in the research and development and production of blood purification equipment and hemodialysis consumables, as well as the construction and operation of chain dialysis centers, and is a drafting unit of national standards and industry standards in the field of blood purification in China, and is an enterprise with a whole industrial chain of blood purification. The products are mainly hemodialysis machine, hemodialysis filter machine, continuous blood purification equipment and blood perfusion machine and other series of blood purification equipment.
According to the prospectus (draft declaration) of Shanwaishan, the number of shares in this public offering does not exceed 36.19 million shares, accounting for no less than 25.00% of the total share capital of the company after the issuance (all the shares in this public offering are new shares, and no old share transfer is carried out). The proposed fundraising is 1.247 billion yuan, and the investment projects of the raised funds are the industrialization project of blood purification equipment and high-value consumables, the construction project of blood purification research and development center, the construction project of marketing network upgrade and remote operation and maintenance service platform, and the supplementary working capital.
It is understood that with the rapid development of the blood purification industry, the scale of operation of Shanwaishan has been expanding in recent years during the reporting period. From 2018 to the end of June 2021, the company achieved operating income of 114 million yuan, 142 million yuan, 254 million yuan and 132 million yuan, and net profit of -27.5406 million yuan, -34.9333 million yuan, 18.3341 million yuan and 3.4056 million yuan, respectively, and achieved rapid growth in operating performance.
Shanwaishan said that in the future, the company will focus on and deeply cultivate the blood purification industry, provide medical institutions and patients with overall blood purification solutions, and is committed to the research and industrialization of blood purification equipment, blood purification consumables, chain hemodialysis centers and hemodialysis center information management systems, and strive to become a world-class blood purification brand. (Shanghai Stock Exchange website, Chongqing Shanwaishan Blood Purification Technology Co., Ltd.)
![Poetry | Spring water crossing, sunset mountain outside the mountain[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)